These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 38955418)

  • 21. A phase II, open-label, single-arm trial of carboplatin plus etoposide with bevacizumab and atezolizumab in patients with extended-stage small-cell lung cancer (CeLEBrATE study): background, design and rationale.
    Andrini E; Lamberti G; Mazzoni F; Riccardi F; Bonetti A; Follador A; Artioli F; Genova C; Barbieri F; Frassoldati A; Brighenti M; Colantonio I; Pasello G; Ficorella C; Cinieri S; Tiseo M; Gelsomino F; Tognetto M; Rihawi K; Ardizzoni A
    Future Oncol; 2022 Mar; 18(7):771-779. PubMed ID: 35068173
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness analysis of atezolizumab plus chemotherapy in the first-line treatment of extensive-stage small-cell lung cancer.
    Zhou K; Zhou J; Huang J; Zhang N; Bai L; Yang Y; Li Q
    Lung Cancer; 2019 Apr; 130():1-4. PubMed ID: 30885327
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase II Study of Roniciclib in Combination with Cisplatin/Etoposide or Carboplatin/Etoposide as First-Line Therapy in Patients with Extensive-Disease Small Cell Lung Cancer.
    Reck M; Horn L; Novello S; Barlesi F; Albert I; Juhász E; Kowalski D; Robinet G; Cadranel J; Bidoli P; Chung J; Fritsch A; Drews U; Wagner A; Govindan R
    J Thorac Oncol; 2019 Apr; 14(4):701-711. PubMed ID: 30677506
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Outcome and Biomarker Analysis from a Multicenter Phase 2 Study of Ipilimumab in Combination with Carboplatin and Etoposide as First-Line Therapy for Extensive-Stage SCLC.
    Arriola E; Wheater M; Galea I; Cross N; Maishman T; Hamid D; Stanton L; Cave J; Geldart T; Mulatero C; Potter V; Danson S; Woll PJ; Griffiths R; Nolan L; Ottensmeier C
    J Thorac Oncol; 2016 Sep; 11(9):1511-21. PubMed ID: 27296105
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.
    Paz-Ares L; Dvorkin M; Chen Y; Reinmuth N; Hotta K; Trukhin D; Statsenko G; Hochmair MJ; Özgüroğlu M; Ji JH; Voitko O; Poltoratskiy A; Ponce S; Verderame F; Havel L; Bondarenko I; Kazarnowicz A; Losonczy G; Conev NV; Armstrong J; Byrne N; Shire N; Jiang H; Goldman JW;
    Lancet; 2019 Nov; 394(10212):1929-1939. PubMed ID: 31590988
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Durable Response to Atezolizumab in Extensive-Stage Small-Cell Lung Cancer Leading to 60 Months Overall Survival: A Case Report.
    Paczkowski F; Raphael J; Browne C
    Curr Oncol; 2024 Jun; 31(7):3682-3689. PubMed ID: 39057143
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of inflamed-phenotype of small cell lung cancer leading to the efficacy of anti-PD-L1 antibody and chemotherapy.
    Shirasawa M; Yoshida T; Shiraishi K; Takigami A; Takayanagi D; Imabayashi T; Matsumoto Y; Masuda K; Shinno Y; Okuma Y; Goto Y; Horinouchi H; Yotsukura M; Yoshida Y; Nakagawa K; Tsuchida T; Hamamoto R; Yamamoto N; Motoi N; Kohno T; Watanabe SI; Ohe Y
    Lung Cancer; 2023 May; 179():107183. PubMed ID: 37037178
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tumor mutational burden adjusted by neutrophil-to-lymphocyte ratio serves as a potential biomarker for atezolizumab-treated patients with extensive stage small cell lung cancer.
    Zhang C; Huo Y; Shang X; Zhang T; Tang N; Wang H
    Respir Res; 2024 Jun; 25(1):253. PubMed ID: 38902698
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer.
    Reck M; Luft A; Szczesna A; Havel L; Kim SW; Akerley W; Pietanza MC; Wu YL; Zielinski C; Thomas M; Felip E; Gold K; Horn L; Aerts J; Nakagawa K; Lorigan P; Pieters A; Kong Sanchez T; Fairchild J; Spigel D
    J Clin Oncol; 2016 Nov; 34(31):3740-3748. PubMed ID: 27458307
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Baseline quality of life and performance status as prognostic factors in patients with extensive-stage disease small cell lung cancer treated with pemetrexed plus carboplatin vs. etoposide plus carboplatin.
    Reck M; Thatcher N; Smit EF; Lorigan P; Szutowicz-Zielinska E; Liepa AM; Winfree KB; Peterson P; Guba SC; Socinski MA
    Lung Cancer; 2012 Dec; 78(3):276-81. PubMed ID: 23043970
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Advancements in Small-cell Lung Cancer: The Changing Landscape Following IMpower-133.
    Pacheco J; Bunn PA
    Clin Lung Cancer; 2019 May; 20(3):148-160.e2. PubMed ID: 30686680
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Carboplatin versus cisplatin in combination with etoposide in the first-line treatment of small cell lung cancer: a pooled analysis.
    Jiang S; Huang L; Zhen H; Jin P; Wang J; Hu Z
    BMC Cancer; 2021 Dec; 21(1):1308. PubMed ID: 34876060
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comprehensive genomic and spatial immune infiltration analysis of survival outliers in extensive-stage small cell lung cancer receiving first-line chemoimmunotherapy.
    Jiang Y; Xie J; Cheng Q; Cai Z; Xu K; Lu W; Wang F; Wu X; Song Y; Lv T; Zhan P
    Int Immunopharmacol; 2024 Nov; 141():112901. PubMed ID: 39151386
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of baseline characteristics on extensive-stage SCLC patients treated with etoposide/carboplatin: A secondary analysis of a phase III study.
    Abdel-Rahman O
    Clin Respir J; 2018 Oct; 12(10):2519-2524. PubMed ID: 30073795
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Randomized phase II study of carboplatin and etoposide with or without obatoclax mesylate in extensive-stage small cell lung cancer.
    Langer CJ; Albert I; Ross HJ; Kovacs P; Blakely LJ; Pajkos G; Somfay A; Zatloukal P; Kazarnowicz A; Moezi MM; Schreeder MT; Schnyder J; Ao-Baslock A; Pathak AK; Berger MS;
    Lung Cancer; 2014 Sep; 85(3):420-8. PubMed ID: 24997137
    [TBL] [Abstract][Full Text] [Related]  

  • 36. FDA Approval Summary: Atezolizumab and Durvalumab in Combination with Platinum-Based Chemotherapy in Extensive Stage Small Cell Lung Cancer.
    Mathieu L; Shah S; Pai-Scherf L; Larkins E; Vallejo J; Li X; Rodriguez L; Mishra-Kalyani P; Goldberg KB; Kluetz PG; Theoret MR; Beaver JA; Pazdur R; Singh H
    Oncologist; 2021 May; 26(5):433-438. PubMed ID: 33687763
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomized phase II study of LY2510924 and carboplatin/etoposide versus carboplatin/etoposide in extensive-disease small cell lung cancer.
    Salgia R; Stille JR; Weaver RW; McCleod M; Hamid O; Polzer J; Roberson S; Flynt A; Spigel DR
    Lung Cancer; 2017 Mar; 105():7-13. PubMed ID: 28236984
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of Carboplatin With Cisplatin in Small Cell Lung Cancer in US Veterans.
    Azar I; Yazdanpanah O; Jang H; Austin A; Kim S; Chi J; Alkassis S; Saha BK; Chopra A; Neu K; Mehdi S; Mamdani H
    JAMA Netw Open; 2022 Oct; 5(10):e2237699. PubMed ID: 36264573
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anlotinib plus etoposide and cisplatin/carboplatin as first-line therapy for extensive-stage small cell lung cancer (ES-SCLC): a single-arm, phase II study.
    Kong T; Chen L; Zhao X; Duan F; Zhou H; Wang L; Liu D
    Invest New Drugs; 2022 Oct; 40(5):1095-1105. PubMed ID: 35788937
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Veliparib in Combination with Carboplatin and Etoposide in Patients with Treatment-Naïve Extensive-Stage Small Cell Lung Cancer: A Phase 2 Randomized Study.
    Byers LA; Bentsion D; Gans S; Penkov K; Son C; Sibille A; Owonikoko TK; Groen HJM; Gay CM; Fujimoto J; de Groot P; Dunbar M; Kang K; He L; Sehgal V; Glasgow J; Bach BA; Ellis PM
    Clin Cancer Res; 2021 Jul; 27(14):3884-3895. PubMed ID: 33947690
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.